Difference between revisions of "Temozolomide (Temodar)"

Revision as of 01:14, 11 December 2021

General information

Class/mechanism: Alkylator. Temozolomide is converted in vivo to the reactive compound 5-(3-methyltriazen- 1-yl)-imidazole-4-carboxamide (MTIC). MTIC causes alkylation of DNA at the O6 and N7 positions of guanine, leading to cell damage and cell death.^[1]^[2]
Route: PO, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

8/11/1999: Initial accelerated approval for treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine.
- 3/15/2005: Converted to regular approval.
Indicated for newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment.
Indicated for refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.

History of changes in EMA indication

1/26/1999: Initial marketing authorization as Temodal.

Also known as

Generic name: TMZ
Brand names: Gliotem, Temcad, Temizole, Temodal, Temodar, Temonat, Temoside, Temoz, Temzol

References

[insert-1] 1.0 ^1.1 ^1.2 Temozolomide (Temodar) package insert

[2] Temozolomide (Temodar) package insert (locally hosted backup)

[3] Temozolomide (Temodar) patient drug information (Chemocare)

[4] Temozolomide (Temodar) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 28: / Line 28: @@
 ==History of changes in FDA indication==
-* 8/11/1999: Initial FDA approval for treatment of adult patients with refractory [[Anaplastic_glioma|anaplastic astrocytoma]], i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine
+* 8/11/1999: Initial accelerated approval for treatment of adult patients with refractory [[Anaplastic_glioma|anaplastic astrocytoma]], i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine.
+**3/15/2005: Converted to regular approval.
 * Indicated for newly diagnosed [[Glioblastoma|glioblastoma multiforme (GBM)]] concomitantly with radiotherapy and then as maintenance treatment.
 * Indicated for refractory [[Anaplastic_glioma|anaplastic astrocytoma]] patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.